Clinical Trial Update: Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Lutetium-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer patients with varying renal function is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: RECRUITING